Susquehanna International Group, LLP My Md Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.22 - $0.58 $16,563 - $43,666	-75,287 Reduced 55.52%	60,319 $15,000
Q3 2023 Nov 14, 2023	SELL	$0.47 - $1.87 $3,082 - $12,263	-6,558 Reduced 4.61%	135,606 $80,000
Q2 2023 Aug 11, 2023	BUY	$1.44 - $2.26 $62,743 - $98,472	43,572 Added 44.19%	142,164 $213,000
Q1 2023 May 16, 2023	BUY	$1.1 - $2.86 $29,728 - $77,294	27,026 Added 37.76%	98,592 $169,000
Q4 2022 Feb 14, 2023	BUY	$0.92 - $96.0 $13,506 - $1.41 Million	14,681 Added 25.81%	71,566 $82,000
Q3 2022 Nov 14, 2022	BUY	$2.22 - $82.2 $79,178 - $2.93 Million	35,666 Added 168.09%	56,885 $148,000
Q2 2022 Aug 15, 2022	SELL	$2.0 - $4.78 $121,452 - $290,270	-60,726 Reduced 74.11%	21,219 $46,000
Q1 2022 May 16, 2022	SELL	$3.34 - $6.05 $114,859 - $208,053	-34,389 Reduced 29.56%	81,945 $382,000
Q4 2021 Feb 14, 2022	BUY	$5.46 - $9.69 $494,266 - $877,187	90,525 Added 350.75%	116,334 $705,000
Q3 2021 Nov 15, 2021	BUY	$4.64 - $7.94 $119,753 - $204,923	25,809 New	25,809 $186,000

30.2K

Ticker MYMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,470,000
Market Cap $67.5M
Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and o...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.